bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 1 from IL4 from T Follicular Helper Cells Downregulates Antitumor Immunity
Authors: Shirota Hidekazu , Klinman Dennis M. , Ito Shuku-ei , Ito Hiroyasu , Kubo Masato , Ishioka Chikashi
Published: April 2023

Supplementary Figure 1. Increased IL-4 and IL-21 expression in tumor draining LNs.
Supplementary Figures S1 through S4 from The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma
Authors: Ascierto Maria Libera , McMiller Tracee L. , Berger Alan E. , Danilova Ludmila , Anders Robert A. , Netto George J. , Xu Haiying , Pritchard Theresa S. , Fan Jinshui , Cheadle Chris , Cope Leslie , Drake Charles G. , Pardoll Drew M. , Taube Janis M. , Topalian Suzanne L.
Published: April 2023

Figure S1: Extraction of paraffin-embedded PD-L1+ RCC tissues for RNA isolation. Figure S2: Molecules previously found to be up-regulated in PD-L1+ vs. PD-L1(-) melanomas are not differentially expressed in PD-L1+ RCCs from patients with divergent clinical outcomes after anti-PD-1 therapy. Figure S3: Gene expression in RCC cell lines. Figure S4: In silico analyses of TCGA RCC data do not demonstrate significant associations between UGT1A6 gene expression and overall survival or clinical stage.
Supplementary Figures 1 - 7 from TLR7 Ligand Augments GM-CSF–Initiated Antitumor Immunity through Activation of Plasmacytoid Dendritic Cells
Authors: Narusawa Megumi , Inoue Hiroyuki , Sakamoto Chika , Matsumura Yumiko , Takahashi Atsushi , Inoue Tomoko , Watanabe Ayumi , Miyamoto Shohei , Miura Yoshie , Hijikata Yasuki , Tanaka Yoshihiro , Inoue Makoto , Takayama Koichi , Okazaki Toshihiko , Hasegawa Mamoru , Nakanishi Yoichi , Tani Kenzaburo
Published: April 2023

PDF file - 316K, Supplementary Fig. S1: Effective depletion of PDCA-1+ cells in mouse splenocytes. Supplementary Fig. S2: Validation of gene expression by quantitative real-time PCR. Supplementary Fig. S3: Effects of TLR ligands on body weight changes in mice treated with subcutaneous injections of LLC/SeV/GM cells. Supplementary Fig. S4: Increased number of TVS-infiltrating PDCA-1+ cells in mice treated with combined irLLC/SeV/GM cells and imiquimod. Supplementary Fig. S5: Increased serum IFN-a level in mice treated with combined irLLC/SeV/GM cells and imiquimod. Supplementary Fig. S6: Prophylactic tumor vaccination using irLLC/SeV/GM cells induced significant antitumor effects in a syngeneic mouse model. Supplementary Fig. S7: Enhanced expression levels of maturation and costimulatory molecules including CCR7, CD40, MHC class I, and MHC class II in tumor cells-derived GM-CSF-sensitized DCs in TDLNs.
Supplementary Fig. S4 from Regulatory T Cells from Colon Cancer Patients Inhibit Effector T-cell Migration through an Adenosine-Dependent Mechanism
Authors: Sundström Patrik , Stenstad Hanna , Langenes Veronica , Ahlmanner Filip , Theander Lisa , Ndah Tapuka Gordon , Fredin Kamilla , Börjesson Lars , Gustavsson Bengt , Bastid Jérémy , Quiding-Järbrink Marianne
Published: April 2023

This supplementary figure shows transendothelial migration of CD4+ and CD8+ T cells in the presence of an A2AR agonist (A) or antagonist (B).
Data Supplement from Cytotoxic T Lymphocytes Block Tumor Growth Both by Lytic Activity and IFNγ-Dependent Cell-Cycle Arrest
Authors: Matsushita Hirokazu , Hosoi Akihiro , Ueha Satoshi , Abe Jun , Fujieda Nao , Tomura Michio , Maekawa Ryuji , Matsushima Kouji , Ohara Osamu , Kakimi Kazuhiro
Published: April 2023

The infiltration of CTLs into the tumor inhibited the tumor growth by both cytolytic and cytostatic activities.
Data Supplement from Cytotoxic T Lymphocytes Block Tumor Growth Both by Lytic Activity and IFNγ-Dependent Cell-Cycle Arrest
Authors: Matsushita Hirokazu , Hosoi Akihiro , Ueha Satoshi , Abe Jun , Fujieda Nao , Tomura Michio , Maekawa Ryuji , Matsushima Kouji , Ohara Osamu , Kakimi Kazuhiro
Published: April 2023

Pmel-1 CTLs produce large amounts of IFN-Î³ but not TNF-Î± in vitro.
Data Supplement from Cytotoxic T Lymphocytes Block Tumor Growth Both by Lytic Activity and IFNγ-Dependent Cell-Cycle Arrest
Authors: Matsushita Hirokazu , Hosoi Akihiro , Ueha Satoshi , Abe Jun , Fujieda Nao , Tomura Michio , Maekawa Ryuji , Matsushima Kouji , Ohara Osamu , Kakimi Kazuhiro
Published: April 2023

Primer pairs used in this study.
Table S2 from Validation of Intratumoral T-bet+ Lymphoid Cells as Predictors of Disease-Free Survival in Breast Cancer
Authors: Mulligan Anna Marie , Pinnaduwage Dushanthi , Tchatchou Sandrine , Bull Shelley B. , Andrulis Irene L.
Published: April 2023

Table S2 gives the relative risks by univariate Cox proportional hazards model of DFS for tri- categorization of T-bet for several (10, 15, 20, 25, 30) cut points. T-bet-/low was associated with reduced DFS at cut point 30 as relative risks and p-values suggested.
Supplementary Table 1 from Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy
Authors: George Daniel J. , Nabhan Chadi , DeVries Todd , Whitmore James B. , Gomella Leonard G.
Published: April 2023

Statistical Modeling Approaches for Survival Subsequent to Disease Progression for Control-Arm Patients Including Parameter Estimates for all Model Terms.
Supplemental Figure 2 from Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity
Authors: Wiehagen Karla R. , Girgis Natasha M. , Yamada Douglas H. , Smith Andressa A. , Chan Szeman Ruby , Grewal Iqbal S. , Quigley Michael , Verona Raluca I.
Published: April 2023

S2. CD45+ Immune infiltrate varies with immunotherapy, while frequencies of CD11b+ myeloid population are not significantly altered.
Supplemental Figure 2 from Neutrophils Increase Oral Squamous Cell Carcinoma Invasion through an Invadopodia-Dependent Pathway
Authors: Glogauer Judah E. , Sun Chun X. , Bradley Grace , Magalhaes Marco A.O.
Published: April 2023

A- Live cell imaging of neutrophil and UMSCC47 co-cultures showing the intimate contact between cancer cells, matrix and neutrophils. The arrows point to neutrophils in close contact with cancer cells and matrix. B- Neutrophil culture showing the neutrophil-mediated matrix degradation. C- Neutrophil and UMSCC47 co-culture showing the dot-like invadopodia-mediated degradation and the neutrophil-mediated degradation. Neutrophils are washed away during fixation and therefore cannot be seen in these images. Cancer cells migrate during the 24h of the experiments and can be seen close to or on top of neutrophil degraded areas. Note that degradation "dots" caused by cancer cells are still visible under the neutrophil-mediated degradation.
Supplementary Figures S1-8 from Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
Authors: Noguchi Takuro , Ward Jeffrey P. , Gubin Matthew M. , Arthur Cora D. , Lee Sang Hun , Hundal Jasreet , Selby Mark J. , Graziano Robert F. , Mardis Elaine R. , Korman Alan J. , Schreiber Robert D.
Published: April 2023

Supplementary Figure S1. Genomic sequence of the PD-L1 locus and expression of immunogenic neoantigens in T3deltaPDL1 lines. Supplementary Figure S2. Expression of PD-L1 and neoantigens in the escape T3deltaPDL1 cells. Supplementary Figure S3. PD-L1 but not PD-L2 is upregulated on MCA sarcomas in vitro and in vivo following exposure to IFNgamma. Supplementary Figure S4. T9-PDL1 cells form progressively growing tumors in WT mice. Supplementary Figure S5. T9-PDL1ovr but not T9-PDL1phy cells inhibit antigen-specific T cell killing in vitro. Supplementary Figure S6. Extrinsic IFNgamma stimulation controls upregulation and maintenance of tumor PD-L1 expression. Supplementary Figure S7. Sixteen immune subsets in MCA sarcomas by flow cytometry. Supplementary Figure S8. Comprehensive analysis of cell types expressing PD-L1 in T3 tumors.
Supplemental Table I from PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells
Authors: Mahoney Kathleen M. , Sun Heather , Liao Xiaoyun , Hua Ping , Callea Marcella , Greenfield Edward A. , Hodi F. Stephen , Sharpe Arlene H. , Signoretti Sabina , Rodig Scott J. , Freeman Gordon J.
Published: April 2023

Supplemental Table I. Description and quantitation of PD-L1 IHC in tumor specimens.
Supplemental Figure and Table Legends from PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells
Authors: Mahoney Kathleen M. , Sun Heather , Liao Xiaoyun , Hua Ping , Callea Marcella , Greenfield Edward A. , Hodi F. Stephen , Sharpe Arlene H. , Signoretti Sabina , Rodig Scott J. , Freeman Gordon J.
Published: April 2023

Supplemental Figure and Table Legends
Supplementary Figures 1 through 8 from Autophagy Inhibition Dysregulates TBK1 Signaling and Promotes Pancreatic Inflammation
Authors: Yang Shenghong , Imamura Yu , Jenkins Russell W. , Cañadas Israel , Kitajima Shunsuke , Aref Amir , Brannon Arthur , Oki Eiji , Castoreno Adam , Zhu Zehua , Thai Tran , Reibel Jacob , Qian Zhirong , Ogino Shuji , Wong Kwok K. , Baba Hideo , Kimmelman Alec C. , Pasca Di Magliano Marina , Barbie David A.
Published: April 2023

Supplementary Figure 1. Characterization of inflammatory cell infiltrates and their recovery with time. Supplementary Figure 2. Negative feedback control of pTBK1 by autophagy. Supplementary Figure 3. pTBK1 levels correlate with underlying levels of basal autophagy. Supplementary Figure 4. Lack of total TBK1 enrichment in autophagosomes. Supplementary Figure 5. Screening of autophagy receptors that regulate selective autophagy of pTBK1. Supplementary Figure 6. MRT67307 or CYT387 treatment inhibits pathogen xenophagy. Supplementary Figure 7. CYT387 treatment inhibits IFNγ induced PD-L1 expression in 8988T cells. Supplementary Figure 8. Jurkat T cell recruitment by exogenous CCL5 or 8988TsgATG5 cells.
Supplementary Figures 1-9 from Ablation of B7-H3 but Not B7-H4 Results in Highly Increased Tumor Burden in a Murine Model of Spontaneous Prostate Cancer
Authors: Kreymborg Katharina , Haak Stefan , Murali Rajmohan , Wei Joyce , Waitz Rebecca , Gasteiger Georg , Savage Peter A. , van den Brink Marcel R. M. , Allison James P.
Published: April 2023

Supplementary Figure 1. Increased B7-H3 and B7-H4 protein expression in murine prostate tumors. Supplementary Figure 2. Higher abundance of neoplastic epithelium in the absence of B7-H3. Supplementary Figure 3. Comparable levels of serum testosterone and AR expression in TRAMP+/- wt and TRAMP+/- B7-H3-/- mice. Supplementary Figure 4. B7-H3 does not influence tumor cell proliferation in a cell-intrinsic manner. Supplementary Figure 5. Immunosuppressive environment in TRAMP+ tumors in the absence of B7-H3. Supplementary Figure 6. B7-H3 does not affect T-cell proliferation or NK or CD8+ T-cell function directly. Supplementary Figure 7. Percentages of FoxP3+ cells in control (brachial) and tumor-draining (periaortic) lymph nodes are the same in TRAMP+wt and TRAMP+B7-H3-/- mice. Supplementary Figure 8. Percentages of NK1.1+, CD8+, CD4+ and CD11c+ cells among TILs in TRAMP+wt and TRAMP+B7-H3-/- mice. Supplementary Figure 9. B7-H3 is expressed by tumor-infiltrating lymphocytes.
Supplemental Methods and Figures 1 - 11 from Three Steps to Breaking Immune Tolerance to Lymphoma: A Microparticle Approach
Authors: Makkouk Amani , Joshi Vijaya B. , Lemke Caitlin D. , Wongrakpanich Amaraporn , Olivier Alicia K. , Blackwell Sue E. , Salem Aliasger K. , Weiner George J.
Published: April 2023

Figure S1. Synthesis and characterization of Dox MPs. Figure S2. Dox MPs enhance phagocytosis of A20 by DCs. Figure S3. Dox MPs exert similar effects to soluble Dox in human cell lines. Figure S4. All therapy components are required for maximum efficacy. Figure S5. Ab dose used is optimal. Figure S6. Three-step therapy and Ab therapy induce comparable tumor necrosis. Figure S7. Three-step therapy induces comparable Treg, cDC and MDSC infiltration into tumors. Figure S8. No differences in T cells were seen in draining lymph nodes. Figure S9. No differences in T cell activation phenotype were seen in draining lymph nodes. Figure S10. No differences in antigen-specific responses were seen in lymphoid tissues. Figure S11. Three-step therapy is efficient at reducing EL4 tumor burdens.
Supplementary Fig. S5 from Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors
Authors: Manuel Edwin R. , Chen Jeremy , D'Apuzzo Massimo , Lampa Melanie G. , Kaltcheva Teodora I. , Thompson Curtis B. , Ludwig Thomas , Chung Vincent , Diamond Don J.
Published: April 2023

Colony forming unit (CFU) enumeration of ST in tumors of mice treated with and without PEGPH20. Mice with 14-day orthotopic KPC tumors (n=3) were given indicated treatment regimens. Tumors were then extracted at indicated time points post-treatment, homogenized in PBS containing a protease inhibitor mix (Roche), plated on LB-0 plates containing appropriate antibiotics, and then incubated at 37ï‚°C overnight. Data is representative of multiple experiments utilizing identical treatments and post-treatment analyses. (A) CFU comparison of mice treated with ST, with and without PEGPH20, at various time points after treatment. (B) Effects of Gr-1 depletion (Gr1-) on accumulation of shIDO-ST in orthotopic KPC tumors in mice treated with and without PEGPH20. Mice were depleted 24hr prior to treatment. Tumors were extracted 48hr post-treatment and homogenized for CFU enumeration. *p<0.05, **p<0.01, 1-way ANOVA.
Supplementary Fig. S4 from Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors
Authors: Manuel Edwin R. , Chen Jeremy , D'Apuzzo Massimo , Lampa Melanie G. , Kaltcheva Teodora I. , Thompson Curtis B. , Ludwig Thomas , Chung Vincent , Diamond Don J.
Published: April 2023

Pathology of peripheral organs in treated mice. Selected organs from mice given indicated treatments were reviewed histopathologically by hematoxylin/eosin stain. The liver shows portal and parenchymal inflammation with occasional foci of coagulative necrosis (N) in mice treated with PEGPH20/shIDO-ST or PEGPH20/shScr-ST, which also show minimal inflammatory changes within kidney (not shown) and pancreas. These findings can be ascribed to the use of Salmonella as a vector, since they are not seen in the PEGPH20 control mice. These findings have been documented previously using VNP20009 (13). Mild splenic hyperplasia is seen in all treated animals. Images shown are representative of multiple experiments.
Supplementary Fig. S10 from Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors
Authors: Manuel Edwin R. , Chen Jeremy , D'Apuzzo Massimo , Lampa Melanie G. , Kaltcheva Teodora I. , Thompson Curtis B. , Ludwig Thomas , Chung Vincent , Diamond Don J.
Published: April 2023

Preliminary testing of PEGPH20/shIDO-ST in autochthonous KPC-Brca1 mouse model. PMN and DAPI immunofluorescence staining of an autochthonous tumor section from a KPC-Brca1 mouse treated with PEGPH20/shIDO-ST. Tumor was excised, flash frozen, sectioned, and stained 5 days following treatment. Central DAPI negative region of tumor with neutrophils (red) is depicted at 10X magnification with DAPI+ tumor cells (blue) at upper right (T).
Supplementary Figure S1 from Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma
Authors: Derks Sarah , Nason Katie S. , Liao Xiaoyun , Stachler Matthew D. , Liu Kevin X. , Liu Jie Bin , Sicinska Ewa , Goldberg Michael S. , Freeman Gordon J. , Rodig Scott J. , Davison Jon M. , Bass Adam J.
Published: April 2023

PD-L2 expression in patient derived xenografts.
Supplementary Figure 3 from Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity
Authors: Bastid Jeremy , Regairaz Anne , Bonnefoy Nathalie , Déjou Cécile , Giustiniani Jérôme , Laheurte Caroline , Cochaud Stéphanie , Laprevotte Emilie , Funck-Brentano Elisa , Hemon Patrice , Gros Laurent , Bec Nicole , Larroque Christian , Alberici Gilles , Bensussan Armand , Eliaou Jean-François
Published: April 2023

Representative IHC staining of CD39 expression in vascular endothelial cells and lymphocytes from various normal tissues (clone HPA014067).
Supplementary Methods from Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness
Authors: Miller Lance D. , Chou Jeff A. , Black Michael A. , Print Cristin , Chifman Julia , Alistar Angela , Putti Thomas , Zhou Xiaobo , Bedognetti Davide , Hendrickx Wouter , Pullikuth Ashok , Rennhack Jonathan , Andrechek Eran R. , Demaria Sandra , Wang Ena , Marincola Francesco M.
Published: April 2023

Detailed description of methods.
Supplementary Movie 1 from αβ TCR-Mediated Recognition: Relevance to Tumor-Antigen Discovery and Cancer Immunotherapy
Authors: Reinherz Ellis L.
Published: April 2023

Supplementary Movie 1. The stationary large cells are epithelial whereas the small motile cells are T lymphocytes performing immune surveillance in search of foreign antigen. Notice how the one centrally disposed T cell is searching along the surface of multiple epithelial cells. This scanning motion generates large tangential physical forces at the membrane interface between T cell and epithelial cell. The speed of the T cell scanning process is close to 10 TCR complex widths per second. Copyright (2002) National Academy of Sciences, U.S.A.
Supplementary Figure S2 from Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness
Authors: Miller Lance D. , Chou Jeff A. , Black Michael A. , Print Cristin , Chifman Julia , Alistar Angela , Putti Thomas , Zhou Xiaobo , Bedognetti Davide , Hendrickx Wouter , Pullikuth Ashok , Rennhack Jonathan , Andrechek Eran R. , Demaria Sandra , Wang Ena , Marincola Francesco M.
Published: April 2023

Cross-cohort comparisons of metagene distributions and tertile thresholds.
Supplementary Tables from Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer
Authors: Kates Max , Nirschl Thomas , Sopko Nikolai A. , Matsui Hotaka , Kochel Christina M. , Reis Leonardo O. , Netto George J. , Hoque Mohammad O. , Hahn Noah M. , McConkey David J. , Baras Alex S. , Drake Charles G. , Bivalacqua Trinity J.
Published: April 2023

Supplementary Table 1: Relative Gene Expression of outlier "immune response" genes after BCG vs no treatment in sorted CD8+ cells from bladder cancer. Supplementary Table 2: Relative Gene Expression of outlier "immune response" genes after BCG vs no treatment in sorted CD4+ cells from bladder cancer.
Supplemental Figure S1 from CARD9 Promotes Sex-Biased Colon Tumors in the APCmin Mouse Model
Authors: Leo Vonny I. , Tan Sze Huey , Bergmann Hanna , Cheah Peh Yean , Chew Min Hoe , Lim Kiat Hon , Ruland Jürgen , Reilly Patrick T.
Published: April 2023

Supplemental Figure S1. Small intestinal tumorigenesis data.
Supplementary Video 3 from Estradiol Promotes Breast Cancer Cell Migration via Recruitment and Activation of Neutrophils
Authors: Vazquez Rodriguez Gabriela , Abrahamsson Annelie , Jensen Lasse Dahl Ejby , Dabrosin Charlotta
Published: April 2023

Video showing how neutrophils closely interact with breast cancer cells in the metastatic niche and participate in breast cancer cells transendothelial migration.
Supplementary Video 2 from Estradiol Promotes Breast Cancer Cell Migration via Recruitment and Activation of Neutrophils
Authors: Vazquez Rodriguez Gabriela , Abrahamsson Annelie , Jensen Lasse Dahl Ejby , Dabrosin Charlotta
Published: April 2023

Video showing how eutrophils aid the intravasation and invasion of breast cancer cells
Supplementary Figure Legend from Follicle-Stimulating Hormone Receptor as a Target in the Redirected T-cell Therapy for Cancer
Authors: Urbanska Katarzyna , Stashwick Caitlin , Poussin Mathilde , Powell Daniel J.
Published: April 2023

Supplementary Figure Legend from Follicle-Stimulating Hormone Receptor as a Target in the Redirected T-cell Therapy for Cancer
Supplemental Table 1 from Molecular Programming of Tumor-Infiltrating CD8+ T Cells and IL15 Resistance
Authors: Doedens Andrew L. , Rubinstein Mark P. , Gross Emilie T. , Best J. Adam , Craig David H. , Baker Megan K. , Cole David J. , Bui Jack D. , Goldrath Ananda W.
Published: April 2023

PyMT tumor CD8+ versus naive gene expression and fold change.
Supplementary Table 1 from The Tumor Microenvironment Shapes Lineage, Transcriptional, and Functional Diversity of Infiltrating Myeloid Cells
Authors: Elpek Kutlu G. , Cremasco Viviana , Shen Hua , Harvey Christopher J. , Wucherpfennig Kai W. , Goldstein Daniel R. , Monach Paul A. , Turley Shannon J.
Published: April 2023

XLSX file - 29K, Supplementary Table S1: Expression values for myeloid cell signature genes from the heatmap in Figure 1E.
Supplementary Figure Legends from The Tumor Microenvironment Shapes Lineage, Transcriptional, and Functional Diversity of Infiltrating Myeloid Cells
Authors: Elpek Kutlu G. , Cremasco Viviana , Shen Hua , Harvey Christopher J. , Wucherpfennig Kai W. , Goldstein Daniel R. , Monach Paul A. , Turley Shannon J.
Published: April 2023

PDF file - 63K
Supplementary Figure 1 from High and Interrelated Rates of PD-L1+CD14+ Antigen-Presenting Cells and Regulatory T Cells Mark the Microenvironment of Metastatic Lymph Nodes from Patients with Cervical Cancer
Authors: Heeren A. Marijne , Koster Bas D. , Samuels Sanne , Ferns Debbie M. , Chondronasiou Dafni , Kenter Gemma G. , Jordanova Ekaterina S. , de Gruijl Tanja D.
Published: April 2023

Triple immunofluorescence staining of CD14 (green), CD163 (red) and PD-L1 (blue) of representative tumor negative (LN-) and positive (LN+) lymph node specimen reveals the presence of elevated numbers of CD14+CD163+ cells expressing PD-L1 in LN+ and low to non-detectable expression levels of PD-L1 on sporadic CD14+CD163+ cells in LN-. (400x magnification, scale bar is 10 µm).
Supplementary figure legends from Natural Killer T-cell Immunotherapy in Combination with Chemotherapy-Induced Immunogenic Cell Death Targets Metastatic Breast Cancer
Authors: Gebremeskel Simon , Lobert Lynnea , Tanner Kaitlyn , Walker Brynn , Oliphant Tora , Clarke Livia E. , Dellaire Graham , Johnston Brent
Published: April 2023

Figure legends for supplementary figures
Supplementary Table 2 from IL32 Is Progressively Expressed in Mycosis Fungoides Independent of Helper T-cell 2 and Helper T-cell 9 Polarization
Authors: Ohmatsu Hanako , Humme Daniel , Gulati Nicholas , Gonzalez Juana , Möbs Markus , Suárez-Fariñas Mayte , Cardinale Irma , Mitsui Hiroshi , Guttman-Yassky Emma , Sterry Wolfram , Krueger James G.
Published: April 2023

PDF file - 316K, Selected upregulated and down regulated genes of IL-32 treated MyLa and HH cells.
Supplementary Figures 1 - 6 from Effector CD8+ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7Rα Dependent
Authors: Johnson C. Bryce , Riesenberg Brian P. , May Bennett R. , Gilreath Stuart C. , Li Guangfu , Staveley-O'Carroll Kevin F. , Garrett-Mayer Elizabeth , Mehrotra Shikhar , Cole David J. , Rubinstein Mark P.
Published: April 2023

Figure S1. Blockade of IL-7 but not IL-2 reduces engraftment of IL-12 conditioned (Tc1) CD8+ T cells in lymphodepleted mice. Figure S2. Blockade of cytokine signaling does not reduce the functionality of donor CD8+ T cells. Figure S3. Activated CD8+ T cells do not require TCR engagement for engraftment in an irradiated host. Figure S4. IL-7 mediated proliferation of Tc1 is STAT5 and PI3K dependent. Figure S5. Tc1 cells generated from IL-7Ralpha+/- and wildtype mice exhibit a similar profile except for IL-7Ralpha expression. Figure S6. The level of TCR stimulation, costimulation, and IL-12 drive IL-7Ralpha expression after CD8+ T cell activation.
Supplementary Figures from Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors
Authors: Voena Claudia , Menotti Matteo , Mastini Cristina , Di Giacomo Filomena , Longo Dario Livio , Castella Barbara , Merlo Maria Elena Boggio , Ambrogio Chiara , Wang Qi , Minero Valerio Giacomo , Poggio Teresa , Martinengo Cinzia , D'Amico Lucia , Panizza Elena , Mologni Luca , Cavallo Federica , Altruda Fiorella , Butaney Mohit , Capelletti Marzia , Inghirami Giorgio , Jänne Pasi A. , Chiarle Roberto
Published: April 2023

Supplementary Figure S1. ALK Tg mice develop lung multifocal adenocarcinomas similar to human ALK-rearranged NSCLC. Supplementary Figure S2. Therapeutic ALK vaccine impairs tumor growth of ALK-rearranged lung tumors. Supplementary Figure S3. Immunophenotype of EML4-ALK transgenic mice Supplementary Figure S4. Human ALK-rearranged NSCLC show a pattern of low expression of T cell markers. Supplementary Figure S5. PD-L1 expression is dependent on ALK kinase activity in ALK-rearranged NSCLC cells. Supplementary Figure S6. Schematic protocols of the in vivo treatment with anti-PD-1 blocking antibody. Supplementary Figure S7. ALK vaccine can be combined with ALK inhibitor TAE684. Supplementary Figure S8. Immunophenotype of intratumoral T cells in ALK vaccinated mice.
Supplementary Table S2 from Survivin Autoantibodies Are Not Elevated in Lung Cancer When Assayed Controlling for Specificity and Smoking Status
Authors: Broodman Ingrid , VanDuijn Martijn M. , Stingl Christoph , Dekker Lennard J.M. , Germenis Anastasios E. , de Koning Harry J. , van Klaveren Rob J. , Aerts Joachim G. , Lindemans Jan , Luider Theo M.
Published: April 2023

Supplementary Table S2. Scaffold 'Sample view' of all proteins and protein clusters identified in protein band 1 to 5.
Supplementary Figure 2 from The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity
Authors: Hudecek Michael , Sommermeyer Daniel , Kosasih Paula L. , Silva-Benedict Anne , Liu Lingfeng , Rader Christoph , Jensen Michael C. , Riddell Stanley R.
Published: April 2023

(A) Cytolytic activity of CD8+ TCM-derived T-cells expressing long/CD28, long/4-1BB, and long/CD28_4-1BB CD19-CARs against K562/CD19, K562, and Raji cells. (B) Cytokine production by CAR-T-cells after co-culturing with Raji cells. Supernatants were obtained after 24 hours for analysis. (C) Proliferation of CD19-CAR-T-cells 72 hours after stimulation with Raji cells by CFSE dye dilution. Numbers above each histogram indicate the number of cell divisions the proliferating subset underwent, and the fraction of T-cells in each gate that underwent {greater than or equal to}4/3/2/1 cell divisions is provided in the upper left of each plot.
Supplemental Materials and Methods from The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity
Authors: Hudecek Michael , Sommermeyer Daniel , Kosasih Paula L. , Silva-Benedict Anne , Liu Lingfeng , Rader Christoph , Jensen Michael C. , Riddell Stanley R.
Published: April 2023

Supplemental Materials and Methods
Supplementary Tables S1 - S5 from Combined Anti-VEGF and Anti–CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes
Authors: Wu Xinqi , Li Jingjing , Connolly Erin M. , Liao Xiaoyun , Ouyang Jing , Giobbie-Hurder Anita , Lawrence Donald , McDermott David , Murphy George , Zhou Jun , Piesche Matthias , Dranoff Glenn , Rodig Scott , Shipp Margaret , Hodi F. Stephen
Published: April 2023

Supplementary Table S1. Clinical responses and survival of patients with durable clinical benefit. Supplementary Table S2. Time between pre-treatment and post-treatment samples and the fold changes for Gal-1 antibodies. Supplementary Table S3. Distribution of patients with humoral immune responses to Gal-1. Supplementary Table S4. The relationship between response and Gal-1 antibody change. Supplementary Table S5. H-scores of Gal-1 staining in pre-treatment and post-treatment tumor biopsies.
Supplementary Figure 1 from PD-1 Blockade Expands Intratumoral Memory T Cells
Authors: Ribas Antoni , Shin Daniel Sanghoon , Zaretsky Jesse , Frederiksen Juliet , Cornish Andrew , Avramis Earl , Seja Elizabeth , Kivork Christine , Siebert Janet , Kaplan-Lefko Paula , Wang Xiaoyan , Chmielowski Bartosz , Glaspy John A. , Tumeh Paul C. , Chodon Thinle , Pe'er Dana , Comin-Anduix Begoña
Published: April 2023

Gating strategy used to analyze immune cell subpopulations within tumor infiltrating lymphocytes. Flow cytometry dot-plots on the left side and a dendrogram displaying the gating strategy of six populations on the right. We gated alive (7AAD negative) singlet cells that were positive for leukocyte antigen (CD45+). Then, the following gating was applied to designate NK cells (CD45+CD56+CD3-), B cells (CD45+CD19/CD20+CD3-), monocytes (CD45+CD14+), and T cells (CD45+CD3+). From the monocytes, a subset of MDSC with low HLA-DR positive cells was used. Finally, T regulatory cells (Treg) were described among CD4+ cells and from those, the CD25+HighCD127Low.
Supplemental Figure Legends from Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas–FasL-Dependent AICD
Authors: Künkele Annette , Johnson Adam J. , Rolczynski Lisa S. , Chang Cindy A. , Hoglund Virginia , Kelly-Spratt Karen S. , Jensen Michael C.
Published: April 2023

Supplemental Figure Legends
Supplemental Figure 3 from Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas–FasL-Dependent AICD
Authors: Künkele Annette , Johnson Adam J. , Rolczynski Lisa S. , Chang Cindy A. , Hoglund Virginia , Kelly-Spratt Karen S. , Jensen Michael C.
Published: April 2023

Supplemental Fig.3. In vitro and in vivo antitumor activity of CD171-specific 2G-CAR spacer variant CD8+ TE(CM) against CD171lowSK-N-DZ human NB xenografts.
Supplementary Materials and Methods and Supplementary Figure Legends from HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment
Authors: Zigler Maya , Shir Alexei , Joubran Salim , Sagalov Anna , Klein Shoshana , Edinger Nufar , Lau Jeffrey , Yu Shang-Fan , Mizraji Gabriel , Globerson Levin Anat , Sliwkowski Mark X. , Levitzki Alexander
Published: April 2023

Supplementary Material and methods
Supplementary Figure S6 from Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20
Authors: Weiskopf Kipp , Anderson Katie L. , Ito Daisuke , Schnorr Peter J. , Tomiyasu Hirotaka , Ring Aaron M. , Bloink Kristin , Efe Jem , Rue Sarah , Lowery David , Barkal Amira , Prohaska Susan , McKenna Kelly M. , Cornax Ingrid , O'Brien Timothy D. , O'Sullivan M. Gerard , Weissman Irving L. , Modiano Jaime F.
Published: April 2023

CV1 does not inhibit proliferation of CLBL-1 cells in vitro.
Supplementary Figure S2 from HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment
Authors: Zigler Maya , Shir Alexei , Joubran Salim , Sagalov Anna , Klein Shoshana , Edinger Nufar , Lau Jeffrey , Yu Shang-Fan , Mizraji Gabriel , Globerson Levin Anat , Sliwkowski Mark X. , Levitzki Alexander
Published: April 2023

Supplementary Figure illustrating the difference in cytokine mRNA and protein expression following treatment of BT-474 with pIC/PPHAffibody and pIC/PPCys
Supplementary Figure S2 from Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20
Authors: Weiskopf Kipp , Anderson Katie L. , Ito Daisuke , Schnorr Peter J. , Tomiyasu Hirotaka , Ring Aaron M. , Bloink Kristin , Efe Jem , Rue Sarah , Lowery David , Barkal Amira , Prohaska Susan , McKenna Kelly M. , Cornax Ingrid , O'Brien Timothy D. , O'Sullivan M. Gerard , Weissman Irving L. , Modiano Jaime F.
Published: April 2023

CD47 expression on canine cancer samples.
Supplementary Figure 8 from Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
Authors: da Silva Ines Pires , Gallois Anne , Jimenez-Baranda Sonia , Khan Shaukat , Anderson Ana C. , Kuchroo Vijay K. , Osman Iman , Bhardwaj Nina
Published: April 2023

PDF file - 59K, Fig. S8. Tim-3 blockade has no effect in NK cell viability but increases the expression of CD16 in these cells.
Supplementary Figure 4 from PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection
Authors: MacFarlane Alexander W. , Jillab Mowafaq , Plimack Elizabeth R. , Hudes Gary R. , Uzzo Robert G. , Litwin Samuel , Dulaimi Essel , Al-Saleem Tahseen , Campbell Kerry S.
Published: April 2023

PDF file - 3477K, Effect of surgery on cellular activation markers. Pre-surgical (time point zero) and post-surgical (at designated weeks after surgery) measurements on the same patients are connected by a line and the statistical significance is calculated by a paired Wilcoxon rank-sum test. Data points from stage 4 patients are marked with black filled diamonds and the data from the single stage 3 patient is shown in grey. Sub-panels are as follows: A) CD69 on T Cells (CD3+ CD45+ CD56-), B) Perforin in CD8+ T Cells, C) Granzyme B in CD8+ T Cells, D) Perforin in CD4+ T Cells, E) Granzyme B in CD56dim NK Cells, F) Perforin in CD56dim NK Cells.
Supplemental Table from PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation
Authors: Joseph Richard W. , Millis Sherri Z. , Carballido Estrella M. , Bryant David , Gatalica Zoran , Reddy Sandeep , Bryce Alan H. , Vogelzang Nicholas J. , Stanton Melissa L. , Castle Erik P. , Ho Thai H.
Published: April 2023

Supplemental Table. Concordance of Immunohistochemical Staining of PD-L1 Expression (130021 vs SP142 antibody) in 19 Renal Cell Carcinomas With Sarcomatoid Differentiation
Supplemental Figure 4: from Cross-talk between 4-1BB and TLR1–TLR2 Signaling in CD8+ T Cells Regulates TLR2′s Costimulatory Effects
Authors: Joseph Ann Mary , Srivastava Ratika , Zabaleta Jovanny , Davila Eduardo
Published: April 2023

Co-administration of agonistic 4-1BB antibody and TLR1-TLR2 ligand reduces growth of B16 melanomas in mice.
Supplementary Figure 2 from Post-Sepsis State Induces Tumor-Associated Macrophage Accumulation through CXCR4/CXCL12 and Favors Tumor Progression in Mice
Authors: Mota José M. , Leite Caio A. , Souza Lucas E. , Melo Paulo H. , Nascimento Daniele C. , de-Deus-Wagatsuma Virginia M. , Temporal Jessica , Figueiredo Florêncio , Noushmehr Houtan , Alves-Filho José C. , Cunha Fernando Q. , Rego Eduardo M.
Published: April 2023

Post-sepsis state led to increased metastatic burden.
Supplementary figures 1-5 from Primary Tumors Limit Metastasis Formation through Induction of IL15-Mediated Cross-Talk between Patrolling Monocytes and NK Cells
Authors: Kubo Hiroshi , Mensurado Sofia , Gonçalves-Sousa Natacha , Serre Karine , Silva-Santos Bruno
Published: April 2023

S1. Primary tumor inhibits experimental metastasis formation. S2. NK cell analysis and anti-NK1.1 antibody-mediated depletion. S3. Contributions of NK versus T cells to IFN-γ production in the lung after metastasis induction. S4. Myeloid subset analysis. S5. Antibody depletion controls and impact on myeloid cells.
Supplementary Tables 1 - 2 from Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
Authors: Boyerinas Benjamin , Jochems Caroline , Fantini Massimo , Heery Christopher R. , Gulley James L. , Tsang Kwong Yok , Schlom Jeffrey
Published: April 2023

Supplementary Table S1. Pre-treating PBMC with IL-2 did not affect ADCC induced by avelumab of the human lung carcinoma cell line H441. Supplementary Table S2. Pre-treating purified NK cells with IL-12 did not increase ADCC activity mediated by avelumab of the human carcinoma cell lines HT29 and ASPC-1 more than the isotype control.
Supplemental Figure Legends from Comprehensive Immune Profiling of Lung Adenocarcinomas Reveals Four Immunosubtypes with Plasma Cell Subtype a Negative Indicator
Authors: Kurebayashi Yutaka , Emoto Katsura , Hayashi Yuichiro , Kamiyama Ikuo , Ohtsuka Takashi , Asamura Hisao , Sakamoto Michiie
Published: April 2023

Figure legends for suppremental Figure 1 to 5.
Supplementary Figure Legends S1-S10 from Interleukin-12 from CD103+ Batf3-Dependent Dendritic Cells Required for NK-Cell Suppression of Metastasis
Authors: Mittal Deepak , Vijayan Dipti , Putz Eva M. , Aguilera Amelia R. , Markey Kate A. , Straube Jasmin , Kazakoff Stephen , Nutt Stephen L. , Takeda Kazuyoshi , Hill Geoffrey R. , Waddell Nicola , Smyth Mark J.
Published: April 2023

Supplementary Figure Legends S1-S10
Supplementary Movie 1 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells
Authors: Davenport Alexander J. , Jenkins Misty R. , Cross Ryan S. , Yong Carmen S. , Prince H. Miles , Ritchie David S. , Trapani Joseph A. , Kershaw Michael H. , Darcy Phillip K. , Neeson Paul J.
Published: April 2023

Movie 1. OT-I cells co-cultured with MC57-OVA257 cells.
Supplementary Figure Legends from Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes
Authors: Kitano Shigehisa , Postow Michael A. , Ziegler Carly G.K. , Kuk Deborah , Panageas Katherine S. , Cortez Czrina , Rasalan Teresa , Adamow Mathew , Yuan Jianda , Wong Philip , Altan-Bonnet Gregoire , Wolchok Jedd D. , Lesokhin Alexander M.
Published: April 2023

PDF file - 81K
Supplementary Figure 1 from CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells
Authors: Davenport Alexander J. , Jenkins Misty R. , Cross Ryan S. , Yong Carmen S. , Prince H. Miles , Ritchie David S. , Trapani Joseph A. , Kershaw Michael H. , Darcy Phillip K. , Neeson Paul J.
Published: April 2023

Supplementary Figure 1. TCR activated OT-I and CAR. OT-I cells display similar expression levels of cytotoxic granules.
Supplementary Figure 2 from Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes
Authors: Kitano Shigehisa , Postow Michael A. , Ziegler Carly G.K. , Kuk Deborah , Panageas Katherine S. , Cortez Czrina , Rasalan Teresa , Adamow Mathew , Yuan Jianda , Wong Philip , Altan-Bonnet Gregoire , Wolchok Jedd D. , Lesokhin Alexander M.
Published: April 2023

PDF file - 58K, Supplemental Figure 2. PBMCs available in multiple aliquots were serially analyzed over 3 weeks to evaluate day-to-day reproducibility of CVHLA-DR measures. A standard error of measurement of 1.4% and 0.7%, respectively for QC sample 1 and 2 was detected.
Supplementary Table S2 from Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies
Authors: Johnson Douglas B. , Lovly Christine M. , Flavin Marisa , Panageas Katherine S. , Ayers Gregory D. , Zhao Zhiguo , Iams Wade T. , Colgan Marta , DeNoble Sarah , Terry Charles R. , Berry Elizabeth G. , Iafrate A. John , Sullivan Ryan J. , Carvajal Richard D. , Sosman Jeffrey A.
Published: April 2023

Mutations assessed at MSKCC.
Supplemental Figure 4 from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors
Authors: Wang Enxiu , Wang Liang-Chuan , Tsai Ching-Yi , Bhoj Vijay , Gershenson Zack , Moon Edmund , Newick Kheng , Sun Jing , Lo Albert , Baradet Timothy , Feldman Michael D. , Barrett David , Puré Ellen , Albelda Steven , Milone Michael C.
Published: April 2023

SS1-KIRS2/DAP12 T cells mediate robust anti-tumor activity in vivo.
Supplementary Figure 2 from Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy
Authors: Trotta Anna Maria , Ottaiano Alessandro , Romano Carmela , Nasti Guglielmo , Nappi Anna , De Divitiis Chiara , Napolitano Maria , Zanotta Serena , Casaretti Rossana , D'Alterio Crescenzo , Avallone Antonio , Califano Daniela , Iaffaioli Rosario Vincenzo , Scala Stefania
Published: April 2023

Progression-free survival was defined as time elapsed between treatment initiation and clinical progression. PFS was 10.8 months in patients whit FcγRIIIa-V158F or FcγRIIIa-V158V vs 5.1 months in patients whit FcγRIIIa-F158F. Log-Rank test for two curves: p=0.050.
Supplementary Figures 1-16 and Legends from T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma—Implications for Adoptive Cell Therapy
Authors: Andersen Rikke , Westergaard Marie Christine Wulff , Kjeldsen Julie Westerlin , Müller Anja , Pedersen Natasja Wulff , Hadrup Sine Reker , Met Özcan , Seliger Barbara , Kromann-Andersen Bjarne , Hasselager Thomas , Donia Marco , Svane Inge Marie
Published: April 2023

S1.(A) The figure shows an image of cancer cells stained with May-GrÃ¼nwald-Giemsa (MGG) after cytospin centrifugation of freshly detached cancer cells from a representative patient (RCC12), magnification x 200. The red arrow shows a mitotic figure. (B) The figure shows images of clotted cancer cells from RCC12 after formalin-fixation and paraffin-embedding followed by immunohistochemistry (IHC) staining for various RCC markers (as seen from the figure). S2. The FACS plots demonstrate CD107a mobilization (left panels) and cytokine production (TNF and IFNgamma right panels) from PBMCs alone (control) and after co-culture with autologous tumor cell line (TCL) in a representative RCC patient (RCC28). Plots are gated on CD3+ cells (left panels) and CD3+ CD8+ cells (right panels). S3. Changes in TIL reactivity during the rapid expansion protocol (REP). S4. The FACS plots demonstrate cytokine production (TNF and IFNgamma) after co-culture assay with autologous tumor cell lines from (A) unselected MM REP-TILs (gated on CD8+ T cells) and (B) CD8+CD107a+ sorted MM REP-TILs in a representative patient. S5. Massive expansion with alternative cytokine combinations S6. Cytolytic activity of RCC-TIL S7. Polyfunctional characterization of CD8+CD107a+ tumor-reactive T cells. S8. Differentiation/dysfunctional profile of CD8+ tumor-reactive Y-TIL S9. Differentiation/dysfunctional profile of CD8+ REP-TIL Up-regulation of HLA class I expression after exposure to IFNgamma S10. Up-regulation of HLA class I expression after exposure to IFNgamma.ï�§ S11. Constitutive expression of the major antigen processing machinery (APM) components in RCC and MM by qPCR. S12. IFNgamma-induced upregulation of the major antigen processing machinery (APM) components in RCC and MM by qPCR. S13. IFNgamma-induced fold induction of the major antigen processing machinery (APM) components in RCC and MM by qPCR. S14. Effects of IFNgamma on autologous tumor recognition by CD8+ T cells. S15. Up-regulation of HLA class II after exposure to IFNgamma in RCC and MM S16. Effects of IFNgamma on autologous tumor recognition by CD4+ T cells.
Table S2 from Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells
Authors: Kouo Theodore , Huang Lanqing , Pucsek Alexandra B. , Cao Minwei , Solt Sara , Armstrong Todd , Jaffee Elizabeth
Published: April 2023

Predicted activation of TNFα, IFNγ, and IL-6 signaling pathways in the KO/KO CD8+ T cells vs. WT/WT CD8+ T cells. Analyses was conducted using Ingenuity IPA software.
Supplementary Methods, Figures 1 - 3, Table 1 from CD4+ T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8+ T-cell Targeting of HER2/neu–Expressing Cancers
Authors: Datta Jashodeep , Xu Shuwen , Rosemblit Cinthia , Smith Jenessa B. , Cintolo Jessica A. , Powell Daniel J. , Czerniecki Brian J.
Published: April 2023

Figure S1: HER2high cells are susceptible to NK-mediated ADCC, but not HER2369-377-sensitized CD8+ T-cell-mediated cytotoxicity. Figure S2: Cell line-specific IFN-γ receptor expression and impact of IFN-γ dose titration on MHC class I expression. Figure S3: Comparative effects of trastuzumab or lapatinib in conjunction with Th1 cytokines on class I and HER2 expression. Table S1: Demographic, tumor, and HLA-A typing characteristics of HER2pos-DCIS patients utilized for in vitro sensitization, recognition, and cytotoxicity assays.
Supplementary Figures 1 - 5 from Untreated Stage IV Melanoma Patients Exhibit Abnormal Monocyte Phenotypes and Decreased Functional Capacity
Authors: Chavan Rahul , Salvador Daniela , Gustafson Michael P. , Dietz Allan B. , Nevala Wendy , Markovic Svetomir N.
Published: April 2023

PDF file - 145K, 1. No differences in the granulocyte and lymphocyte populations when comparinguntreated MM patients and HV 2.Gating strategy for monocyte subsets. 3.Gating strategy for HLA-DR expression on monocytes 4.Expression of CD83 and CD86 on dendritic cells when comparing untreated MM patients and HV. 5. Expression of HLA-DR on dendritic cells when comparing untreated MM patients and HV.
Supplementary Methods, Figure Legends from The Promotion of Breast Cancer Metastasis Caused by Inhibition of CSF-1R/CSF-1 Signaling Is Blocked by Targeting the G-CSF Receptor
Authors: Swierczak Agnieszka , Cook Andrew D. , Lenzo Jason C. , Restall Christina M. , Doherty Judy P. , Anderson Robin L. , Hamilton John A.
Published: April 2023

PDF file - 114K
Supplementary Figure 7 from The Promotion of Breast Cancer Metastasis Caused by Inhibition of CSF-1R/CSF-1 Signaling Is Blocked by Targeting the G-CSF Receptor
Authors: Swierczak Agnieszka , Cook Andrew D. , Lenzo Jason C. , Restall Christina M. , Doherty Judy P. , Anderson Robin L. , Hamilton John A.
Published: April 2023

PDF file - 106K, Supplementary Figure 7: CSF-1R expression and breast cancer survival.
Supplementary Figure 4 from The Promotion of Breast Cancer Metastasis Caused by Inhibition of CSF-1R/CSF-1 Signaling Is Blocked by Targeting the G-CSF Receptor
Authors: Swierczak Agnieszka , Cook Andrew D. , Lenzo Jason C. , Restall Christina M. , Doherty Judy P. , Anderson Robin L. , Hamilton John A.
Published: April 2023

PDF file - 120K, Supplementary Figure 4: The oral CSF-1R inhibitor, CYC11645, increases metastasis to lung.
Supplementary Figure Legend and Supplementary Table 1 from Antibody-Mediated Phosphatidylserine Blockade Enhances the Antitumor Responses to CTLA-4 and PD-1 Antibodies in Melanoma
Authors: Freimark Bruce D. , Gong Jian , Ye Dan , Gray Michael J. , Nguyen Van , Yin Shen , Hatch Michaela M.S. , Hughes Christopher C.W. , Schroit Alan J. , Hutchins Jeff T. , Brekken Rolf A. , Huang Xianming
Published: April 2023

Supplementary Figure Legend. Table 1. Antibodies for flow cytometry and immunohistochemistry.
Supplementary Figures from Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1–Resistant Tumors Leading to Tumor Eradication
Authors: Arina Ainhoa , Karrison Theodore , Galka Eva , Schreiber Karin , Weichselbaum Ralph R. , Schreiber Hans
Published: April 2023

Suppl. Figure 1. A. Tumors that escape an equilibrium caused by CD8 T cells targeting tumor stroma are not Ag-loss variants. B. The Ag-specific lytic function of 2C cells in vivo has not declined in mice bearing escaping tumors. C. Equilibrium can be achieved in mice lacking perforin Suppl. Figure 2. PD-L1 but not Tim3 blocking in vitro partially reverses the ability of tumor-infiltrating CD8+ T cells to produce cytokines. Suppl. Figure 3. A second transfer of CD8+ T cells following tumor irradiation or anti-Gr1 antibody therapy cannot prevent tumor escape. Suppl. Figure 4. Cancer cells are negative for MHC-II in vitro but can up-regulate MHC-II in tumors in vivo.
Supplementary Methods, Figure Legends from Enhancing Efficacy of Anticancer Vaccines by Targeted Delivery to Tumor-Draining Lymph Nodes
Authors: Jeanbart Laura , Ballester Marie , de Titta Alexandre , Corthésy Patricia , Romero Pedro , Hubbell Jeffrey A. , Swartz Melody A.
Published: April 2023

PDF file - 254K
Supplementary Figure 6 from Enhancing Efficacy of Anticancer Vaccines by Targeted Delivery to Tumor-Draining Lymph Nodes
Authors: Jeanbart Laura , Ballester Marie , de Titta Alexandre , Corthésy Patricia , Romero Pedro , Hubbell Jeffrey A. , Swartz Melody A.
Published: April 2023

PDF file - 22K, As the tumor progresses, OVA expression decreases in the tumor.